The trial enrolled 620 patients with previously untreated metastatic non-small cell lung cancer, each confirmed to have a PD-L1 tumor proportion score of at least 50 percent, a threshold that generally predicts strong responsiveness to immune checkpoint inhibitors. Patients with EGFR, ALK or ROS1 alterations were excluded, since those molecular subgroups are typically managed with targeted therapies rather than immunotherapy alone. Participants were randomized to receive either the investigational combination or pembrolizumab by itself. In the experimental arm, sacituzumab govitecan was administered at a dose of 10 mg/kg intravenously on days 1 and 8 of each cycle, alongside pembrolizumab at 200 mg on day 1 of every 21-day cycle. The study was open-label, and its dual primary endpoints were progression-free survival as assessed by blinded independent central review and overall survival.

The efficacy data revealed a pattern that has become familiar in oncology trials that miss their primary goals: encouraging numerical trends that ultimately fail the test of statistical rigor. Median progression-free survival by blinded independent central review was 11.8 months for patients receiving the combination, compared with 7.7 months for those receiving pembrolizumab alone, corresponding to a hazard ratio of 0.81 with a 95 percent confidence interval of 0.66 to 1.00 and a P value of 0.0252. Although patients on the combination lived a median of roughly four months longer without their disease progressing, the result did not cross the prespecified threshold for statistical significance that the trial design demanded.

The interim overall survival analysis was even less encouraging. Median overall survival was 21.5 months in the sacituzumab govitecan plus pembrolizumab arm versus 22.8 months with pembrolizumab alone, yielding a hazard ratio of 1.07 with a 95 percent confidence interval of 0.85 to 1.35 and a P value of 0.7155. In other words, the addition of the antibody-drug conjugate produced no survival advantage at this stage of analysis, and the point estimate actually leaned slightly in favor of monotherapy. For a field in which overall survival remains the ultimate benchmark, that finding will weigh heavily on any decision about whether the combination deserves a place in clinical practice.

Secondary measures of tumor response told a somewhat more favorable story. The confirmed objective response rate was 55.6 percent for the combination compared with 43.7 percent for pembrolizumab alone, meaning a substantially larger share of patients experienced meaningful tumor shrinkage when the antibody-drug conjugate was added. The disease control rate, reported in the study table, was 83.3 percent versus 73.1 percent, respectively. Yet the duration of those responses was nearly identical between the arms, with a median duration of response of 21.4 months for the combination and 21.3 months for pembrolizumab alone. The pattern suggests that while the combination could induce responses in more patients, it did not make the responses that occurred last any longer.

Safety findings added another layer of complexity to the interpretation. Treatment-related adverse events occurred in 93.2 percent of patients receiving the combination compared with 65.4 percent of those on pembrolizumab alone. More strikingly, grade 3 or higher treatment-related adverse events affected 55.7 percent of patients in the combination arm versus 16.5 percent in the monotherapy arm, a more than threefold increase in severe toxicity. The most common treatment-related adverse events in the combination arm included anemia, alopecia, neutropenia, diarrhea and nausea, a profile consistent with the known toxicity signature of sacituzumab govitecan. Investigators reported that the safety profile was consistent with the known profiles of the individual agents, with no new or additional toxicities observed when the two drugs were given together.

Giannis Mountzios, M.D., of the Henry Dunant Hospital Center in Athens, Greece, who presented the findings, acknowledged the tension embedded in the data. While the combination of sacituzumab govitecan and pembrolizumab produced a numerically longer progression-free survival and a higher response rate, he noted, EVOKE-03/KEYNOTE-D46 did not meet statistical significance for its primary progression-free survival endpoint, and overall survival was not significantly improved at this interim analysis. He emphasized that these findings provide important information as the field continues to evaluate treatment strategies for patients with PD-L1-high metastatic non-small cell lung cancer, framing the negative result as a contribution to knowledge rather than simply a failed experiment.

The scientific rationale behind the trial was compelling enough to justify a large Phase 3 investment. Sacituzumab govitecan links a topoisomerase I inhibitor payload to an antibody targeting TROP-2, a protein widely expressed on many epithelial cancers, including a substantial proportion of non-small cell lung tumors. The drug has already secured regulatory approvals in previously treated metastatic settings, and combining antibody-drug conjugates with immune checkpoint inhibitors has become one of the most active areas of clinical research, based on the hypothesis that chemotherapy payload-induced tumor cell death can release antigens and render tumors more visible to the immune system. Pembrolizumab, an anti-PD-1 antibody, is the established first-line standard for metastatic non-small cell lung cancer with PD-L1 tumor proportion scores of 50 percent or greater when no targetable alterations are present.

Dr. Mountzios concluded that, despite a numerical improvement in progression-free survival and a higher response rate, sacituzumab govitecan plus pembrolizumab did not meet statistical significance for progression-free survival compared with pembrolizumab monotherapy in patients with untreated PD-L1-high metastatic non-small cell lung cancer, and that overall survival also did not meet statistical significance at the interim analysis. The results leave pembrolizumab monotherapy in its longstanding position as the reference standard for this population, while raising difficult questions about whether the modest numerical gains in progression-free survival justify the substantially higher toxicity burden and the absence of any demonstrated survival benefit. For now, the trial stands as a reminder that in modern oncology, promising biology and early signals do not guarantee success when subjected to the discipline of a randomized Phase 3 test.

The International Association for the Study of Lung Cancer, founded in 1974, is the only global organization dedicated solely to the study of lung cancer and other thoracic malignancies, with a membership of more than 10,000 lung cancer specialists across all disciplines in over 100 countries. The association publishes the Journal of Thoracic Oncology and convenes the World Conference on Lung Cancer, the world’s largest meeting dedicated to lung cancer and other thoracic malignancies, which attracts nearly 7,000 researchers, physicians and specialists from more than 100 countries each year. The conference serves as the venue where pivotal trial results such as EVOKE-03/KEYNOTE-D46 are first unveiled, shaping treatment guidelines and research agendas worldwide. As the oncology community digests these findings, attention will turn to whether further analyses, biomarker-driven subgroup explorations or alternative combination strategies can eventually translate the promise of antibody-drug conjugates into durable first-line benefits for patients with advanced lung cancer.

Subject of Research: Phase 3 testing of sacituzumab govitecan plus pembrolizumab versus pembrolizumab monotherapy as first-line treatment for PD-L1-high metastatic non-small cell lung cancer

Article Title: Sacituzumab govitecan plus pembrolizumab does not meet primary endpoints in first-line PD-L1-high metastatic NSCLC

Article References: Sacituzumab govitecan plus pembrolizumab does not meet primary endpoints in first-line PD-L1-high metastatic NSCLC. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: sacituzumab govitecan, pembrolizumab, non-small cell lung cancer, PD-L1, EVOKE-03, KEYNOTE-D46, antibody-drug conjugate, immunotherapy, progression-free survival, overall survival, Phase 3 trial, IASLC

In April 2022, the landscape of urothelial carcinoma treatment underwent a transformation with the approval of enfortumab vedotin for adults with locally advanced or metastatic forms of the disease who had already undergone prior therapy. This marked a notable advance in treatment options, as enfortumab vedotin brought a targeted therapeutic approach that integrates an antibody-drug conjugate design to combat this challenging cancer. Recently, in September 2024, a new development arose as this drug was approved in conjunction with pembrolizumab for patients facing unresectable or metastatic urothelial carcinoma as a part of first-line therapy.

Notably, the German Institute for Quality and Efficiency in Health Care (IQWiG) has undertaken a comprehensive benefit assessment to analyze whether the combination of enfortumab vedotin and pembrolizumab provides an additional benefit over existing standard treatments. Such assessments are critical in determining the clinical efficacy and safety profile of new treatment modalities while aiding healthcare providers and patients in making informed decisions regarding treatment options.

The findings of IQWiG’s assessment revealed promising insights, particularly in terms of overall survival for patients with urothelial carcinoma who are ineligible for cisplatin therapy, a common chemotherapy option. The data suggest a substantial survival advantage associated with the combination therapy, indicating a ‘major added benefit’ for this subset of patients. This recognition marks a significant milestone in therapeutic assessments, as it is the first instance where the institute designated a ‘major’ benefit label in this indication, highlighting the potential of this new therapeutic approach to markedly improve patient outcomes.

For patients deemed suitable for cisplatin-based therapy, the assessment indicated an added benefit as well, although quantification of this advantage remains elusive. The nuanced evaluation of treatment efficacy underlines the complexity of individual patient profiles and treatment contexts, suggesting that even within standard treatment frameworks, new combination therapies could offer differentiated benefits.

One of the pivotal components in the assessment was a study featuring participants with unresectable or metastatic urothelial carcinoma, who were stratified based on their eligibility for platinum-containing chemotherapy. In this study, patients were randomized to receive either enfortumab vedotin in combination with pembrolizumab or standard chemotherapy regimens involving cisplatin-gemcitabine or carboplatin-gemcitabine, depending on their suitability for cisplatin. The design of this study illuminated important dynamics in treatment response and has implications for clinical practice.

Importantly, the study’s design did not include conventional maintenance treatment with avelumab for patients who remained free of disease progression after completing chemotherapy. Such maintenance therapies are integral to the standard care practices employed for these patients. This oversight is reminiscent of the evolving landscape of cancer treatment approval timelines, illustrating how new therapies can emerge and alter study protocols and patient management strategies.

The initial study commenced in March 2020, prior to the approval of avelumab as a maintenance therapy for this specific indication—an approval that came in June 2020 for the United States and January 2021 for Europe. In response to this evolving treatment context, the manufacturer adapted its study protocol to explicitly acknowledge the possibility of maintenance therapy within the comparator group, even though avelumab was not actively included among the study medications. These adaptations are critical for ensuring the relevance and interpretability of study outcomes.

Through sensitivity analyses, the manufacturers made strides to address the contingencies surrounding the absence of maintenance therapy with avelumab in some comparator patients. Such analyses allow for a more nuanced interpretation of the overall survival outcomes, thereby underscoring the robustness of the data available for the early assessment of the new combination therapy.

The results of these assessments evidence significant treatment advantages, especially for patients who cannot undergo cisplatin-based regimens. Clinical data consistently depict a substantial survival benefit, further augmented by the fact that such advantages persist even amidst varying contexts in maintenance treatment application throughout the study. Additionally, the assessment outlined improvements across various morbidity outcomes and health-related quality of life indicators, while also considering the trade-offs related to specific adverse effects associated with the therapies.

Katrin Nink, the Head of the Oncology Division at IQWiG, emphasized the monumental nature of awarding a ‘major added benefit’ for a dual therapy approach in this therapeutic indication for the first time. This acknowledgment reflects an important shift toward favoring treatment strategies that offer substantial improvement in survival and quality of life, particularly for patients facing daunting diagnoses with limited therapeutic options.

As the dossier assessment progresses under the auspices of the Act on the Reform of the Market for Medicinal Products (AMNOG), the outcome will undergo additional scrutiny through a commenting period overseen by the Federal Joint Committee (G-BA). Following this phase, a final determination regarding the extent of the added benefit of enfortumab vedotin in combination with pembrolizumab will be made, signaling significant implications for future treatment protocols and patient access to these emerging therapies.

In essence, the combination of enfortumab vedotin and pembrolizumab epitomizes a shifting paradigm in the treatment landscape for urothelial carcinoma, demonstrating the potential of novel therapeutic alliances to drive meaningful improvements in patient survival and quality of life. The unfolding developments illustrate a commitment to advancing care for patients battling urothelial carcinoma, marking a significant chapter in oncology that continually seeks to leverage emerging science for better patient outcomes.

Subject of Research: Urothelial Carcinoma Treatment
Article Title: Breakthrough Combination Therapy Shows Major Survival Advantage for Urothelial Carcinoma
News Publication Date: October 2024
Web References: IQWiG
References:
Image Credits:

Keywords: Urothelial carcinoma, enfortumab vedotin, pembrolizumab, chemotherapy, overall survival, cancer treatment, IQWiG, G-BA, healthcare, urothelium.